The 22.84x sales multiple is mechanically depressed by a single $673.1M revenue quarter that prior analysis suggests is non-recurring; on an ex-milestone annualized revenue base of roughly $36-40M, the effective sales multiple would be several multiples higher, implying investors are pricing pipeline optionality rather than current economics. EV/EBITDA is unavailable because pre-milestone EBITDA is negative, so the absence of an EV/EBITDA print is itself informative — it indicates no peer group in this cohort has reached positive EBITDA, and relative valuation must lean on cash-adjusted enterprise value and pipeline stage rather than earnings-based screens. Compared with peers, Nurix's richer P/B may reflect its suddenly cash-rich balance sheet rather than superior franchise value, and warrants investigation into whether the market is discounting the milestone cash for execution risk on remaining development programs.

The near-100% gross margin is characteristic of milestone licensing income carrying negligible direct cost, and therefore says nothing about the earning power of Nurix's underlying pre-commercial business, which has posted operating losses averaging roughly -$70M per quarter across the nine preceding periods. Adjusting for the one-time event, normalized operating margin remains deeply negative at approximately -200% to -400% on the ex-milestone revenue base, so true earning power still depends on pipeline commercialization that has not yet materialized. Analysts should treat the reported profitability signals as reflecting a single cash event and instead monitor sequential R&D and SG&A efficiency — costs that escalated about 75% over two years — as the more meaningful indicator of operating leverage trajectory.

Pre-milestone, ROIC has consistently hovered between roughly -9% and -18% for two years, indicating the company has been compounding losses on invested capital rather than building returns — a pattern typical of clinical-stage biotechs whose R&D spend ($79.3M in 2026Q3 alone) generates no near-term revenue. The 118.8% post-milestone ROIC should not be extrapolated: with $673M of episodic revenue flowing through a ~$1.2B asset base, the ratio is a numerator artifact, and investors should discount it heavily when modeling forward return on the enlarged capital base. The key judgment is whether the milestone cash can be redeployed into programs that lift the underlying ROIC above zero; absent that, the long-run return profile remains dilutive, consistent with retained losses of -$630.1M still anchoring equity quality.

With no meaningful interest coverage data reported and total debt of just $65.3M against milestone-inflated cash of $720.2M, refinancing risk appears minimal for the foreseeable runway; on recent operating cost levels of roughly $110-120M per quarter, the cash position implies an estimated 8-9 quarters of funding. However, the leverage comfort is somewhat superficial: had the milestone not arrived, rising debt against a shrinking equity base during loss-making quarters would have pushed D/E materially higher, so investors should not extrapolate the current 0.07 print as a durable structural feature. The more consequential balance sheet signal is the 90% collapse in deferred revenue from $85.4M to $8.6M over two years, which suggests contracted revenue visibility is thinning even as the balance sheet appears strong — a divergence that warrants monitoring ahead of any debt-sustainability narrative.

Because current and quick ratios are identical across every reported quarter, the company's liquidity is essentially cash-based with negligible inventory dependence — appropriate for a pre-commercial biotech, but it also means liquidity is only as durable as the partnership cash that produced it. Under severe stress — say, a pipeline setback combined with a return to the ~$110-120M quarterly cost base — the $720M treasury would absorb multiple years of losses without forcing dilutive financing, providing genuine downside protection compared with peers like ARVN at a $441M market cap. The judgment call for analysts is whether the elevated current ratio signals balance sheet strength or idle capital; with minimal deployment evident beyond $2.7M in buybacks and a single $38.4M acquisition, the market may eventually pressure management on return-of-capital or business-development discipline.